Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market ...

Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain over the past week, has finalized its licensing and collaboration agreement ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, ...

Holt-Oram syndrome is a condition that affects one out of every 100,000 people. It is rare, but it runs in Nicole Urteaga’s ...

Walmart has already updated its social media accounts to reflect the new logo and wordmark, leading to critical and confused reactions from users. One shared the “before and after” images of ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...

Sarepta Therapeutics (NASDAQ:SRPT) develops RNA-targeted and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy and ongoing research into new genetic therapies.

The Spire Inc. (NYSE: SR) board of directors declared a quarterly common stock dividend of $0.785 per share, payable April 2, 2025, to shareholders of record on March 11, 2025.

RBC believes today’s update should not spark any concerns about any new adverse events or change to the existing benefit/risk of the drug. It keeps an Outperform rating on Sarepta with a $165 ...